PREVENTING MDR GRAM-NEGATIVE HOSPITAL ACQUIRED INFECTIONS

Desarrollado por: Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Descripción

Unmet Need:

Hospital acquired infections are leading cause of non-cardiac death in intensive care units (ICUs).

Proposed Solution:

New synthetic glycoconjugate preventing (ICU)-acquired infections by eliciting protective immunity against MDR bacteria.

Highlights

  • Synthetic polymer able to elicit  protective immunity against MDR

  • Faster developed immunity than vaccines

  • Cost-effective treatment resulting in potential savings to the health system 

Aplicaciones

The present invention relates to the field of therapeutics and, more in particular, to agents and compositions for the prevention and/or treatment of infections caused by bacteria. But the group is currently working in other applications of interest.

Estado de protección

The study has shown that removal of anti-Gal antibodies mediated by GAS prevents sepsis and reduces cytokine levels in mice genetically modified so as to express anti-Gal antibodies.

It has also been tested successfully in human serum, showing increased bactericidal capacity in GAS-pre-treated serums. Toxicity preclinical studies in house have been performed in primates successfully.

IP status: patent ongoing in national phases

Responsable: Área de Desarrollo de Negocio e Innovación

Oficina de Transferencia de Tecnología

Contacto (Tel./mail): 93 260 71 06 / Innovacio@idibell.cat

Estado:
Comercializado, En desarrollo
Tecnología sanitaria:
Medicamentos - Farma